Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by PTC Therapeutics, Inc. of its shares of common stock for up to an aggregate amount of $125 million. The common stock is listed on The Nasdaq Global Select Market under the symbol “PTCT.”

Based in Plainfield, New Jersey, PTC Therapeutics is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders.

The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Yasin Keshvargar and associates Michael Despres and David Li. The tax team included counsel Leslie J. Altus and associate Joseph M. Gerstel. The intellectual property and technology team included partner Pritesh P. Shah and associate Hilary Smith. All members of the Davis Polk team are based in the New York office.

Copy link to share post